People who do not have multiple sclerosis can never fully understand what it is like living with MS. What they can show us is empathy. MS & Me Media presents: Empathy #MSAwareness#WeHaveMS@MSPurposeRadio https://t.co/4TNDNOCK6Q
MS Focus is hosting a virtual Q&A event led by Aaron Boster, MD, on Tues., Nov. 22nd, at 6:30 pm EST.
@AaronBosterMD is a board-certified Neurologist specializing in MS, making him the perfect person to answer your MS-related questions!
Pre-register now: https://t.co/ieqznoGvlQ
Every time you have a lesion in a nerve pathway, surviving nerves are required to compensate for the damage 🧠
Discover more about MS progression and the best known ways to prevent it, featuring @tripping_onair and @GavinGiovannoni 👉 https://t.co/5cMdOxWyZI
#MultipleSclerosis
This study from Oklahoma City Veterans Affairs of 279 PwMS showed that taking medication consistently was associated with lower mortality. "In the good adherence group, patients lived for a median of 52 years [after diagnosis]" Confounded data? https://t.co/zAIIrRjhaH
Part of having strength is knowing that you can’t be strong all the time. Living with MS is hard. We can fake smiles and push through the pain, but sometimes we break…and that’s OK. We’re only human.
monoclonal antibodies are effective for covid-19 in people taking b-cell depleters (ocrevus, rituximab, kesimpta) based on this observational study (5% of those treated hospitalized vs. 39.2% of those untreated hospitalized per this observational study) https://t.co/PR0AlQFWPW
Tixagevimab and Cilgavimab (Evusheld) is an option for people with MS taking b-cell depleters (kesimpta/ocrevus/rituximab) who have a poor antibody response to covid-19 vaccines (image is pre and post antibody titers). https://t.co/FMA2b8tzpn
The availability of 15 subsidised DMTs in Australia has transformed the quality of life of people with MS. 💊
Unfortunately, this is not the case for New Zealanders with MS, who only have access to four DMTs.
Read more 👉 https://t.co/Kdp6weoKbA
#MS#RealMSResearch#VoiceForMS